| 臺大學術典藏 |
2020-10-14T07:24:37Z |
Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study
|
Wong J.-M.; SHU-CHEN WEI; Wang H.-Y.; Yen H.-H.; Hsu W.-H.; Lin H.-H.; Lin J.-K.; Chuang C.-H.; Huang T.-Y.; Chou J.-W.; Lin W.-C. |
| 臺大學術典藏 |
2020-09-23T06:22:46Z |
Differentiating solitary pulmonary metastases in patients with extrapulmonary neoplasmas using FDG-PET
|
Hsu W.-H.;Hsu N.-Y.;Shen Y.-Y.;Ruoh-Fang Yen;Kao C.-H.; Hsu W.-H.; Hsu N.-Y.; Shen Y.-Y.; RUOH-FANG YEN; Kao C.-H. |
| 臺大學術典藏 |
2020-08-14T03:15:32Z |
Management of Crohn's disease in Taiwan: Consensus guideline of the Taiwan society of inflammatory bowel disease
|
Lin J.-K.; Lin W.-C.; Ni Y.-H.; Shieh M.-J.; I-LUN SHIH; Shun C.-T.; Tsang Y.-M.; Wang C.-Y.; Wang H.-Y.; Weng M.-T.; Wu D.-C.; Wu W.-C.; Yen H.-H.; Wong J.-M.; Lin C.-C.; Huang T.-Y.; Hsu T.-C.; Hsu W.-H.; Chuang C.-H.; Chou Y.-H.; Chou J.-W.; Chen J.-S.; Chao T.-H.; Chang T.-A.; Wei S.-C.; Wei S.-C.;Chang T.-A.;Chao T.-H.;Chen J.-S.;Chou J.-W.;Chou Y.-H.;Chuang C.-H.;Hsu W.-H.;Huang T.-Y.;Hsu T.-C.;Lin C.-C.;Lin H.-H.;Lin J.-K.;Lin W.-C.;Ni Y.-H.;Shieh M.-J.;I-Lun Shih;Shun C.-T.;Tsang Y.-M.;Wang C.-Y.;Wang H.-Y.;Weng M.-T.;Wu D.-C.;Wu W.-C.;Yen H.-H.;Wong J.-M.; Lin H.-H. |
| 臺大學術典藏 |
2020-08-13T06:33:46Z |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; Chang Y.-C.; Yu C.-J.; JIN-YUAN SHIH; Lin C.-C.; Chen K.-Y.; Ho C.-C.; Laio W.-Y.; Yang P.-C.; Yang J.C.-H.; Lee J.-H. |
| 臺大學術典藏 |
2020-08-13T06:33:33Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Yang J.C.; Yu C.-J.; JIN-YUAN SHIH; Lin C.-C.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Chen K.-Y.; Liao W.-Y.; Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Jin-Yuan Shih;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C. |
| 臺大學術典藏 |
2020-08-13T06:33:24Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Tsai T.-H.; Chen K.-Y.; Ho C.-C.; Liao W.-Y.; Yang C.-Y.; Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Jin-Yuan Shih;Yang J.C.-H.;Yu C.-J.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; JIN-YUAN SHIH; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-08-13T06:33:24Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yu C.-J.; Yang J.C.-H.; JIN-YUAN SHIH; Lin C.-C.; Lee J.-H.; Hsu W.-H.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu C.-L.; Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Jin-Yuan Shih;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H. |
| 臺大學術典藏 |
2020-08-12T07:46:56Z |
Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists
|
Chen C.-Y.; On the behalf of Taiwan Clinical Trial Consortium for Respiratory Diseases (TCORE); Lai C.-C.; HAO-CHIEN WANG; Chen L.; Yu C.-J.; Yu C.-J.; HAO-CHIEN WANG; Perng D.-W.; Cheng S.-L.; Hsu J.-Y.; Hsu W.-H.; Tsai Y.-H.; Hsiue T.-R.; Lin M.-C.; Lin H.-I.; Wang C.-Y.; Chang Y.-C.; Yang U.-C.; Chen C.-M.; Lin C.-S.; Chen L.; Wei Y.-F.; Chong I.-W.; Wang Y.-H.; Lin Y.S.; Wang C.-Y.; Wang C.-Y.;Lin Y.S.;Wang Y.-H.;Lai C.-C.;Hao-Chien Wang;Chen L.;Yu C.-J.;Yu C.-J.;Hao-Chien Wang;Perng D.-W.;Cheng S.-L.;Hsu J.-Y.;Hsu W.-H.;Tsai Y.-H.;Hsiue T.-R.;Lin M.-C.;Lin H.-I.;Wang C.-Y.;Chang Y.-C.;Yang U.-C.;Chen C.-M.;Lin C.-S.;Chen L.;Wei Y.-F.;Chong I.-W.;Chen C.-Y.;On The Behalf Of Taiwan Clinical Trial Consortium For Respiratory Diseases (Tcore) |
| 臺大學術典藏 |
2020-08-12T06:34:18Z |
Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists
|
Wang C.-Y.; Lin Y.S.; Wang Y.-H.; Lai C.-C.; Wang H.-C.; Chen L.; CHONG-JEN YU; CHONG-JEN YU; Wang H.-C.; Perng D.-W.; Cheng S.-L.; Hsu J.-Y.; Hsu W.-H.; Tsai Y.-H.; Hsiue T.-R.; Lin M.-C.; Lin H.-I.; Wang C.-Y.; Chang Y.-C.; Yang U.-C.; Chen C.-M.; Lin C.-S.; Chen L.; Wei Y.-F.; Chong I.-W.; Chen C.-Y.; On the behalf of Taiwan Clinical Trial Consortium for Respiratory Diseases (TCORE); Wang C.-Y.;Lin Y.S.;Wang Y.-H.;Lai C.-C.;Wang H.-C.;Chen L.;Chong-Jen Yu;Chong-Jen Yu;Wang H.-C.;Perng D.-W.;Cheng S.-L.;Hsu J.-Y.;Hsu W.-H.;Tsai Y.-H.;Hsiue T.-R.;Lin M.-C.;Lin H.-I.;Wang C.-Y.;Chang Y.-C.;Yang U.-C.;Chen C.-M.;Lin C.-S.;Chen L.;Wei Y.-F.;Chong I.-W.;Chen C.-Y.;On The Behalf Of Taiwan Clinical Trial Consortium For Respiratory Diseases (Tcore) |
| 臺大學術典藏 |
2020-08-12T06:34:15Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Hsu C.-C.; Wu C.-T.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Yang C.-Y.; Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Chong-Jen Yu; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; CHONG-JEN YU |
| 臺大學術典藏 |
2020-08-12T02:50:41Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Chao-Chi Ho;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; CHAO-CHI HO; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-08-12T02:50:36Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.; Wu C.-T.; Chang Y.-L.; Yang C.-Y.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y. |
| 臺大學術典藏 |
2020-08-12T02:50:35Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.;Liao W.-Y.;Chao-Chi Ho;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; CHAO-CHI HO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-08-07T01:43:04Z |
Elderly Adults with Late-Onset Ulcerative Colitis Tend to Have Atypical, Milder Initial Clinical Presentations but Higher Surgical Rates and Mortality: A Taiwan Society of Inflammatory Bowel Disease Study
|
Wong J.-M.; Lin W.-C.; CHIEN-CHIH TUNG; Lin H.-H.; Lin C.-C.; Chang C.-W.; Yen H.-H.; Chuang C.-H.; Hsu W.-H.; Tsai W.-S.; Wang H.-Y.; Lin J.-K.; Wei S.-C. |
| 臺大學術典藏 |
2020-07-21T06:46:29Z |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
Yang J.C.-H.; Lee J.-H.; Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; Chang Y.-C.; Yu C.-J.; Shih J.-Y.; Lin C.-C.; Chen K.-Y.; CHAO-CHI HO; Laio W.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2020-07-21T06:46:21Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin C.-C.; Lee J.-H.; Chang Y.-L.; Su K.-Y.; Hsu W.-H.; Hsu C.-L.; Tsai T.-H.; Chen K.-Y.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; CHAO-CHI HO; Liao W.-Y.; Yu C.-J.; Yang J.C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-07-21T06:46:15Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.; Chang Y.-L.; Su K.-Y.; Hsu C.-L.; Liu Y.-N.; Chen K.-Y.; Tsai T.-H.; Liao W.-Y.; CHAO-CHI HO; Yang C.-Y. |
| 臺大學術典藏 |
2020-07-21T06:25:17Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Liao W.-Y.; Ho C.-C.; Liao B.-C.; Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tzu-Hsiu Tsai;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Yang J.C.; Yu C.-J.; Shih J.-Y.; Lin C.-C.; Lee J.-H.; Chang Y.-L.; Su K.-Y.; Hsu W.-H.; Hsu C.-L.; TZU-HSIU TSAI; Chen K.-Y. |
| 臺大學術典藏 |
2020-07-21T06:09:13Z |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
Yang J.C.-H.; Chang Y.-C.; Yu C.-J.; Shih J.-Y.; Lin C.-C.; Chen K.-Y.; Ho C.-C.; WEI-YU LIAO; Yang P.-C.; Chen H.-Y.; Hsu W.-H.; Lin Y.-L.; Lee J.-H.; Lee J.-H.;Lin Y.-L.;Hsu W.-H.;Chen H.-Y.;Chang Y.-C.;Yu C.-J.;Shih J.-Y.;Lin C.-C.;Chen K.-Y.;Ho C.-C.;Wei-Yu Liao;Yang P.-C.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-07-21T06:09:08Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Wei-Yu Liao;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Su K.-Y.;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; WEI-YU LIAO; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-07-21T06:09:03Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Chen K.-Y.; Tsai T.-H.; Ho C.-C.; WEI-YU LIAO; Yang C.-Y.; Yang C.-Y.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yu C.-J.; Yang J.C.-H.; Shih J.-Y.; Lin C.-C.; Lee J.-H.; Hsu W.-H.; Liao B.-C.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C. |
| 臺大學術典藏 |
2020-07-21T05:40:29Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.; Lee J.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Ching-Yao Yang;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; CHING-YAO YANG; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H. |
| 臺大學術典藏 |
2020-06-30T08:51:15Z |
High expression of high-mobility group box 1 in the blood and lungs is associated with the development of chronic obstructive pulmonary disease in smokers
|
Ko H.-K.;Hsu W.-H.;Hsieh C.-C.;Lien T.-C.;Tzong-Shyuan Lee;Kou Y.R.; Ko H.-K.; Hsu W.-H.; Hsieh C.-C.; Lien T.-C.; TZONG-SHYUAN LEE; Kou Y.R. |
| 臺大學術典藏 |
2020-06-30T08:09:57Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Kang-Yi Su;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; KANG-YI SU; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-06-30T08:09:52Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Kang-Yi Su;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; KANG-YI SU; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
